Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06699966 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stony Brook Medicine Anti-Inflammatory Trial

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jun 2030 to Jun 2031
    • Start date: Jan 2026 to Jun 2027
    • Study completion date: Jan 2031 to Jan 2032
    v3
  2. Primary completion date: Jun 30, 2027 to Jun 2030
    • Start date: Jun 30, 2025 to Jan 2026
    • Study completion date: Dec 30, 2028 to Jan 2031
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.
Trial Details
NCT Number NCT06699966
Lead Sponsor Stony Brook University
Conditions
(from sponsor)		 Major Depressive Disorder
Related terms Major Depressive Disorder
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov